IMG Biosciences enacts massive lay-offs after Phase I trial failure
Following the negative Phase I trial outcome for its autoimmune disease treatment, the company is cutting 73% of jobs.
PMLiVE27m
Eli Lilly and Alchemab Therapeutics partner to develop new ALS therapies
Eli Lilly and Alchemab Therapeutics have partnered to develop new therapies for amyotrophic lateral sclerosis (ALS). The ...
ProMIS Neurosciences Initiates Phase 1b Clinical Trial (PRECISE-AD) in Alzheimer’s Disease
ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on developing precision therapies for neurodegenerative diseases, today announced the initiation of its Phase 1b ...